| Project/Area Number |
18K09297
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56040:Obstetrics and gynecology-related
|
|---|
| Research Institution | Fujita Health University (2019-2022)
Keio University (2018) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2020: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Keywords | 卵巣癌 / 薬物療法 / バイオマーカー |
|---|
| Outline of Final Research Achievements |
We developed a novel treatment strategy of neoadjuvant chemotherapy (NAC) consisting of dose-dense paclitaxel+carboplatin and bevacizumab that has anti-angiogenic activity for advanced ovarian cancer patients. This therapy was well tolerated, and a satisfactory rate of complete resection by interval debulking surgery (IDS) was achieved. We investigated an effective patient population for bevacizumab therapy with chemotherapy for recurrent ovarian cancer, and found that some adverse events were high in Japanese population. We established diagnostic laparoscopic surgery as a minimally invasive method to determine the molecular biological characteristics of ovarian cancer, and searched for therapeutic targets by comprehensive genome sequencing using collected specimens.
|
| Academic Significance and Societal Importance of the Research Achievements |
近年のがん治療は臨床ゲノムシークエンスを用いたゲノムバイオマーカーの解析が進められ、個々の遺伝子情報に基づく薬剤選択を行う臓器横断的な治療開発にシフトしつつある。しかしながら、このような個別化治療の有用性については、臨床試験による科学的な検証が行われ始めたばかりであり、婦人科がんを対象としたデータは限定的である。本研究は生物学的に多様な卵巣癌における治療標的の探索、個別化治療の実現に有用なデータをもたらすものと考える。
|
